Novacyt (ALNOV.PA) Stock Price

Novacyt Price

Euronext·CLOSED
0.00GBP+0.0001 (+3.02 %)
Market closed

Over the last 16 years Novacyt grew revenue by 28.9% annually, reaching 19.63 M GBP. For Novacyt, the net margin of -212.7% is down versus 47.8% a few years ago. The consensus 12-month price target for Novacyt is 3.57 GBP, about 99,919.1% above where the stock trades today. Of 7 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 30% above its 52-week low.

Novacyt stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Novacyt over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Novacyt stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Novacyt's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Novacyt Stock Price History
DateNovacyt Price
7/14/20260.00 GBP
7/13/20260.00 GBP
7/10/20260.00 GBP
7/9/20260.00 GBP
7/8/20260.00 GBP
7/7/20260.00 GBP
7/6/20260.00 GBP
7/3/20260.00 GBP
7/2/20260.00 GBP
7/1/20260.00 GBP
6/30/20260.00 GBP
6/29/20260.00 GBP
6/26/20260.00 GBP
6/25/20260.00 GBP
6/24/20260.00 GBP
6/23/20260.00 GBP
6/22/20260.00 GBP
6/19/20260.00 GBP
6/18/20260.00 GBP
6/17/20260.00 GBP
6/16/20260.00 GBP
6/15/20260.00 GBP
6/12/20260.00 GBP
6/11/20260.00 GBP
6/10/20260.00 GBP
6/9/20260.00 GBP
6/8/20260.00 GBP
6/5/20260.00 GBP
6/4/20260.00 GBP
6/3/20260.00 GBP
6/2/20260.00 GBP
6/1/20260.00 GBP
5/29/20260.01 GBP
5/28/20260.01 GBP
5/27/20260.01 GBP
5/26/20260.01 GBP
5/25/20260.01 GBP
5/22/20260.01 GBP
5/21/20260.00 GBP
5/20/20260.01 GBP
5/19/20260.01 GBP
5/18/20260.00 GBP
5/15/20260.00 GBP
5/14/20260.00 GBP
5/13/20260.01 GBP
5/12/20260.01 GBP
5/11/20260.01 GBP
5/8/20260.00 GBP
5/7/20260.00 GBP
5/6/20260.00 GBP
5/5/20260.00 GBP
5/4/20260.00 GBP
4/30/20260.00 GBP
4/29/20260.00 GBP
4/28/20260.00 GBP
4/27/20260.00 GBP
4/24/20260.00 GBP
4/23/20260.00 GBP
4/22/20260.00 GBP
4/21/20260.00 GBP
4/20/20260.00 GBP
4/17/20260.00 GBP
4/16/20260.00 GBP
4/15/20260.00 GBP
4/14/20260.00 GBP
4/13/20260.00 GBP
4/10/20260.00 GBP
4/9/20260.00 GBP
4/8/20260.00 GBP
4/7/20260.00 GBP
4/2/20260.00 GBP
3/27/20260.00 GBP
3/26/20260.00 GBP
3/25/20260.00 GBP
3/24/20260.00 GBP
3/23/20260.00 GBP
3/20/20260.00 GBP
3/19/20260.00 GBP
3/18/20260.00 GBP
3/17/20260.00 GBP
3/16/20260.00 GBP
3/13/20260.00 GBP
3/12/20260.00 GBP
3/11/20260.00 GBP
3/10/20260.00 GBP
3/9/20260.00 GBP
3/6/20260.00 GBP
3/5/20260.00 GBP
3/4/20260.00 GBP
3/3/20260.00 GBP
3/2/20260.00 GBP
2/27/20260.00 GBP
2/26/20260.00 GBP
2/25/20260.00 GBP
2/24/20260.00 GBP
2/23/20260.00 GBP
2/20/20260.00 GBP
2/19/20260.00 GBP
2/18/20260.00 GBP
2/17/20260.00 GBP
2/16/20260.00 GBP
2/13/20260.00 GBP
2/12/20260.00 GBP
2/11/20260.00 GBP
2/10/20260.00 GBP
2/9/20260.00 GBP
2/6/20260.00 GBP
2/5/20260.00 GBP
2/4/20260.00 GBP
2/3/20260.00 GBP
2/2/20260.00 GBP
1/30/20260.00 GBP
1/29/20260.00 GBP
1/28/20260.00 GBP
1/27/20260.00 GBP
1/26/20260.00 GBP
1/23/20260.00 GBP
1/22/20260.00 GBP
1/21/20260.00 GBP
1/20/20260.00 GBP
1/19/20260.00 GBP
1/16/20260.00 GBP
1/15/20260.00 GBP
1/14/20260.00 GBP
1/13/20260.00 GBP
1/12/20260.00 GBP
1/9/20260.00 GBP
1/8/20260.00 GBP
1/7/20260.00 GBP
1/6/20260.00 GBP
1/5/20260.00 GBP
1/2/20260.00 GBP
12/31/20250.00 GBP
12/30/20250.00 GBP
12/29/20250.00 GBP
12/24/20250.00 GBP
12/23/20250.00 GBP
12/22/20250.00 GBP
12/19/20250.00 GBP
12/18/20250.00 GBP
12/17/20250.00 GBP
12/16/20250.00 GBP
12/15/20250.00 GBP
12/12/20250.00 GBP
12/11/20250.00 GBP
12/10/20250.00 GBP
12/9/20250.00 GBP
12/8/20250.00 GBP
12/5/20250.00 GBP
12/4/20250.00 GBP
12/3/20250.00 GBP
12/2/20250.00 GBP
12/1/20250.00 GBP
11/28/20250.00 GBP
11/27/20250.00 GBP
11/26/20250.00 GBP
11/25/20250.00 GBP
11/24/20250.00 GBP
11/21/20250.00 GBP
11/20/20250.00 GBP
11/19/20250.00 GBP
11/18/20250.00 GBP
11/17/20250.00 GBP
11/14/20250.00 GBP
11/13/20250.00 GBP
11/12/20250.00 GBP
11/11/20250.00 GBP
11/10/20250.00 GBP
11/7/20250.00 GBP
11/6/20250.00 GBP
11/5/20250.00 GBP
11/4/20250.00 GBP
11/3/20250.00 GBP
10/31/20250.00 GBP
10/30/20250.00 GBP
10/29/20250.00 GBP
10/28/20250.00 GBP
10/27/20250.00 GBP
10/24/20250.00 GBP
10/23/20250.00 GBP
10/22/20250.00 GBP
10/21/20250.00 GBP
10/20/20250.00 GBP
10/17/20250.00 GBP
10/16/20250.00 GBP
10/15/20250.00 GBP
10/14/20250.00 GBP
10/13/20250.00 GBP
10/10/20250.00 GBP
10/9/20250.00 GBP
10/8/20250.00 GBP
10/7/20250.00 GBP
10/6/20250.00 GBP
10/3/20250.00 GBP
10/2/20250.00 GBP
10/1/20250.00 GBP
9/30/20250.00 GBP
9/29/20250.00 GBP
9/26/20250.00 GBP
9/25/20250.00 GBP
9/24/20250.00 GBP
9/23/20250.00 GBP
9/22/20250.00 GBP
9/19/20250.00 GBP
9/18/20250.00 GBP
9/17/20250.00 GBP
9/16/20250.00 GBP
9/15/20250.00 GBP
9/12/20250.00 GBP
9/11/20250.00 GBP
9/10/20250.00 GBP
9/9/20250.00 GBP
9/8/20250.00 GBP
9/5/20250.00 GBP
9/4/20250.00 GBP
9/3/20250.00 GBP
9/2/20250.00 GBP
9/1/20250.00 GBP
8/29/20250.00 GBP
8/28/20250.00 GBP
8/27/20250.00 GBP
8/26/20250.00 GBP
8/25/20250.00 GBP
8/22/20250.00 GBP
8/21/20250.00 GBP
8/20/20250.00 GBP
8/19/20250.00 GBP
8/18/20250.00 GBP
8/15/20250.00 GBP
8/14/20250.00 GBP
8/13/20250.00 GBP
8/12/20250.00 GBP
8/11/20250.00 GBP
8/8/20250.00 GBP
8/7/20250.00 GBP
8/6/20250.00 GBP
8/5/20250.00 GBP
8/4/20250.00 GBP
8/1/20250.00 GBP
7/31/20250.00 GBP
7/30/20250.00 GBP
7/29/20250.00 GBP
7/28/20250.00 GBP
7/25/20250.00 GBP
7/24/20250.00 GBP
7/23/20250.00 GBP
7/22/20250.00 GBP
7/21/20250.00 GBP
7/18/20250.00 GBP
7/17/20250.00 GBP
7/16/20250.00 GBP
Access this data via the Eulerpool API
Get Free API Key

Novacyt Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
12.20 M GBP
-848,800.00 GBP
-4.21 M GBP
Jan 1, 2019
11.47 M GBP
-1.18 M GBP
-5.75 M GBP
Jan 1, 2020
277.20 M GBP
174.69 M GBP
132.42 M GBP
Jan 1, 2021
92.60 M GBP
1.26 M GBP
-9.73 M GBP
Jan 1, 2022
21.04 M GBP
-14.11 M GBP
-25.73 M GBP
Jan 1, 2023
10.62 M GBP
-14.12 M GBP
-28.29 M GBP
Jan 1, 2024
19.63 M GBP
-14.85 M GBP
-41.76 M GBP
Jan 1, 2025 (e)
21.12 M GBP
2.19 M GBP
4.90 M GBP

Novacyt Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 16, 2026, 12:31 AM
 
REVENUEM GBP
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM GBP
NET INCOMEM GBP
NET INCOME GROWTH%
SHARESM
2010201120122013201420152016201720182019202020212022202320242025e
–––1.004.008.009.0011.0012.0011.00277.0092.0021.0010.0019.0021.00
––––300.00100.0012.5022.229.09-8.332,418.18-66.79-77.17-52.3890.0010.53
–––3,200.0025.0050.0055.5654.5558.3363.6476.1730.4323.8130.00168.42168.42
32.0032.0032.0032.001.004.005.006.007.007.00211.0028.005.003.0032.0035.37
–––-1.00-3.00-13.00-4.00-4.00-4.00-5.00132.00-9.00-25.00-28.00-41.004.00
––––200.00333.33-69.23––25.00-2,740.00-106.82177.7812.0046.43-109.76
0.130.152.432.934.446.7912.0923.0837.6645.7368.1970.6370.6370.6370.6370.63
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Novacyt generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Novacyt retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Novacyt's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Novacyt has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Novacyt's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Novacyt stock margins

The Novacyt margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Novacyt. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Novacyt.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
62.23 %
-6.96 %
-34.53 %
Jan 1, 2019
64.00 %
-10.25 %
-50.13 %
Jan 1, 2020
76.30 %
63.02 %
47.77 %
Jan 1, 2021
30.48 %
1.36 %
-10.51 %
Jan 1, 2022
27.31 %
-67.05 %
-122.29 %
Jan 1, 2023
32.87 %
-132.94 %
-266.38 %
Jan 1, 2024
163.39 %
-75.64 %
-212.73 %
Jan 1, 2025 (e)
163.39 %
10.38 %
23.22 %

Novacyt Stock Revenue, EBIT, Earnings per Share

The Novacyt earnings per share therefore indicates how much revenue Novacyt has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.32 GBP
-0.02 GBP
-0.11 GBP
Jan 1, 2019
0.25 GBP
-0.03 GBP
-0.13 GBP
Jan 1, 2020
4.07 GBP
2.56 GBP
1.94 GBP
Jan 1, 2021
1.31 GBP
0.02 GBP
-0.14 GBP
Jan 1, 2022
0.30 GBP
-0.20 GBP
-0.36 GBP
Jan 1, 2023
0.15 GBP
-0.20 GBP
-0.40 GBP
Jan 1, 2024
0.28 GBP
-0.21 GBP
-0.59 GBP
Jan 1, 2025 (e)
0.30 GBP
0.03 GBP
0.07 GBP

Novacyt business model & stock analysis

Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. The company was founded in 2006 and has experienced impressive growth since then. Its headquarters are located in Paris. Novacyt's business model revolves around the development and marketing of diagnostic products and technologies, particularly molecular diagnostic kits and reagents used for identification and quantification of microorganisms, viruses, and genetic differences. These products are commonly used in medical research, clinical diagnostics, and environmental analysis. Novacyt is divided into several divisions, each offering different products and services. Its diagnostic business specializes in the research, development, and marketing of molecular diagnostic kits, including the Primerdesign Kits specifically designed for COVID-19 identification. The company also provides laboratory and service offerings, such as DNA sequencing, qPCR analysis, sample preparation, and PCR disinfection. Additionally, Novacyt offers various diagnostic tests capable of detecting genetic differences and mutations. Its PathFlow division focuses on improving the process from diagnosis to therapy and follow-up, particularly for oncology patients. In response to the COVID-19 pandemic, Novacyt quickly launched a PCR test kit for COVID-19, which has been approved in numerous countries worldwide. Novacyt has successfully established itself as a key player in the fight against the pandemic. In summary, Novacyt SA is a leading biotechnology company specializing in the development and marketing of diagnostic products and technologies. Through its divisions, the company ensures the optimal utilization of molecular diagnostic tests. Novacyt has become an important player in the fight against the pandemic through its rapid response and development of molecular diagnostic kits for COVID-19, establishing itself as a reliable and innovative partner for medical research and clinical diagnostics.

Novacyt SWOT Analysis

Strengths

Novacyt SA has a strong global presence, with operations in several countries and a diverse customer base.

The company has a strong brand reputation and a track record of developing high-quality diagnostic products.

Novacyt SA has a skilled and experienced workforce, which enables it to innovate and adapt quickly to changing market dynamics.

Weaknesses

One of the weaknesses of Novacyt SA is its dependence on a few key customers, which exposes it to the risk of losing significant revenue if any of those customers switch to competitors.

The company may face challenges in maintaining regulatory compliance across different markets due to variations in regulations.

Novacyt SA operates in a highly competitive industry, which can put pressure on pricing and profit margins.

Opportunities

There is a growing demand for diagnostic products and services globally, presenting an opportunity for Novacyt SA to expand its market share.

The company can explore strategic partnerships or acquisitions to enhance its product portfolio and reach new markets.

Advancements in technology and increasing awareness of preventive healthcare can create opportunities for Novacyt SA to develop innovative diagnostic solutions.

Threats

The COVID-19 pandemic has resulted in increased competition in the diagnostic testing market, which can pose a threat to Novacyt SA's market position.

Supply chain disruptions or shortages of raw materials can impact the company's production and delivery capabilities.

Changes in healthcare policies or reimbursement rates can affect the demand and pricing of Novacyt SA's products.

Novacyt Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Novacyt historical P/E ratio, EBIT multiple, and P/S ratio

Novacyt annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Novacyt shares outstanding

The number of shares of Novacyt was 70.63 M in 2025. This indicates how many shares Novacyt is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
37.66 M Stocks
Jan 1, 2019
45.73 M Stocks
Jan 1, 2020
68.19 M Stocks
Jan 1, 2021
70.63 M Stocks
Jan 1, 2022
70.63 M Stocks
Jan 1, 2023
70.63 M Stocks
Jan 1, 2024
70.63 M Stocks
Jan 1, 2025 (e)
70.63 M Stocks

Current Novacyt forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy0.00 % (0)
Hold28.57 % (2)
Sell71.43 % (5)
12M Price Target
0.04
Last Price
0.00
Currency
GBP
12M Return Potential
900.19 %
LTM Return
0 %

Novacyt Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/16/2017-0.09GBP7.10 MGBP2017 Q2
4/27/20170.06GBP6.09 MGBP2016 Q4

Novacyt shareholder structure

% Name
0.04811%
Crinelli (Jean-Pierre Jacques)
Crinelli (Jean-Pierre Jacques)
0.01291%
Gibson (Steve)
Gibson (Steve)
0.00000%
American Century Investment Management, Inc.
American Century Investment Management, Inc.

Novacyt Executives and Management Board

LR

Mr. Lyn Rees

(50)

Chief Executive Officer, Executive Director · since 2023

Compensation108,008.00 GBP
JT

Ms. Juliet Thompson

Independent Non-Executive Director

Compensation48,925.00 GBP
JC

Mr. Jean-Pierre Crinelli

(74)

Independent Non-Executive Director · since 2021

Compensation34,037.00 GBP
JB

Dr. John Brown

Non-Executive Chairman of the Board · since 2023

Compensation15,242.00 GBP
SG

Mr. Steve Gibson

(42)

Chief Financial Officer, Company Secretary, Director

Frequently asked questions about Novacyt

Novacyt SA's business model revolves around the development, manufacturing, and distribution of innovative diagnostic solutions. As a global leader in clinical diagnostics, Novacyt focuses on providing fast, accurate, and easy-to-use testing solutions for infectious diseases, primarily respiratory infections. The company's broad range of products includes molecular and protein-based diagnostic tests, which are utilized by healthcare professionals worldwide to identify and monitor various diseases. Novacyt's business model is built on continuous innovation, strategic partnerships, and a commitment to delivering high-quality diagnostic solutions to improve patient outcomes. With its comprehensive portfolio and strong market presence, Novacyt SA is dedicated to advancing the field of diagnostics and meeting the evolving needs of the healthcare industry.

All fundamentals and in-depth analysis of Novacyt

Our stock analysis for Novacyt stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Novacyt. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Novacyt Stock
Novacyt Revenue→
Novacyt Stock
Novacyt Net Income→
Novacyt Stock
Novacyt P/E→
Novacyt Stock
Novacyt P/S→
Novacyt Stock
Novacyt EBIT→
Novacyt Stock
Novacyt Dividend→
Novacyt Stock
Novacyt Directors Dealings→
Novacyt Stock
Novacyt Stocks→
Novacyt Stock
Novacyt Market capitalization→
Novacyt Stock
Novacyt Debt→
Novacyt Stock
Novacyt Liabilities→
Novacyt Stock
Novacyt Equity→
Novacyt Stock
Novacyt AAQS→
Novacyt Stock
Novacyt Employees→
Novacyt Stock
Novacyt ROE→
Novacyt Stock
Novacyt ROA→
Novacyt Stock
Novacyt ROCE→
Novacyt Stock
Novacyt News→
Novacyt Stock
Novacyt Analyst Price Targets→

Health Stocks

NovartisNovAccess GlobalNovartis AG ADRNovaBridge BiosciencesNovartis IndiaNovaBay PharmaceuticalsNovavaxNova Eye MedicalNovelix PharmaceuticalsNouveau Life PharmaceuticalsNovelstem InternationalNoul CoAll Stocks A–Z →